IQVIA Holdings Inc. (IQV)
| Market Cap | 31.61B |
| Revenue (ttm) | 15.70B |
| Net Income (ttm) | 1.24B |
| Shares Out | 170.00M |
| EPS (ttm) | 6.92 |
| PE Ratio | 26.86 |
| Forward PE | 15.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,195,173 |
| Open | 187.40 |
| Previous Close | 187.22 |
| Day's Range | 185.48 - 189.27 |
| 52-Week Range | 134.65 - 248.03 |
| Beta | 1.32 |
| Analysts | Strong Buy |
| Price Target | 229.15 (+23.22%) |
| Earnings Date | Oct 30, 2025 |
About IQV
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to ... [Read more]
Financial Performance
In 2024, IQVIA Holdings's revenue was $15.41 billion, an increase of 2.81% compared to the previous year's $14.98 billion. Earnings were $1.37 billion, an increase of 1.10%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for IQV stock is "Strong Buy." The 12-month stock price target is $229.15, which is an increase of 23.22% from the latest price.
News
IQVIA: A Positive Long-Term Outlook Despite Trump Legislation
Companies and institutions continue to conduct clinical trials, indicating that the CRO market demand will continue to grow. The revenues of the TAS segment increased by 7.67% in the first half of 202...
IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA names Michael Fedock as financial chief
IQVIA Holdings on Tuesday named insider Michael Fedock as Chief Financial Officer, effective February 28, 2026, succeeding Ron Bruehlman who is set to retire.
IQVIA Announces CFO Transition in Early 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the li...
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass.
The Big 3: BLDR, IQV, LOW
Jessica Inskip expects Jackson Hole this week to be a big market mover. She also sees a potential path for interest rates during the meeting adding momentum to the homebuilder space, including Builder...
IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes
RESEARCH TRIANGLE PARK, N.C. & PLEASANTON, Calif.--(BUSINESS WIRE)--IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced global clinical and commercial partnerships and the complete resolu...
IQVIA: Q2 Earnings Exceeded My Expectations
IQVIA Holdings Inc.'s Q1 results highlighted strong profitability, robust TAS growth, and a healthy backlog, reaffirming its leadership in healthcare data and analytics. Despite sector headwinds, I re...
IQVIA Holdings Inc. (IQV) Q2 2025 Earnings Call Transcript
IQVIA Holdings Inc. (NYSE:IQV) Q2 2025 Earnings Conference Call July 22, 2025 9:00 AM ET Company Participants Ari Bousbib - CEO & Chairman Kerri Joseph - Corporate Participant SVP of Investment Relat...
IQVIA beats quarterly estimates on resilient demand for healthcare analytics
Contract research firm IQVIA Holdings posted second-quarter profit and revenue above Wall Street expectations on Tuesday, as demand rose for its healthcare data and analytics services, sending shares ...
IQVIA Reports Second-Quarter 2025 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA: Competition Is Creating More Challenges Over The Long Haul
I rate IQVIA as a hold due to long-term competitive threats, particularly from one player, and concerns about capital allocation and high debt. IQVIA's business model is solid, but declining gross mar...
IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement'
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA Launches New AI Agents for Life Sciences and Healthcare
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?
IQVIA (IQV) is currently in Phase 18 of its 18-Phase Adhishthana Cycle. On the surface, the stock might appear poised for a new move, but when analyzed through a multi-timeframe lens using the Adhisht...
IQVIA Announces Pricing of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,00...
IQVIA Announces Offering of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 thr...
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026 AUSTIN, Texas , May 27, 2025 /P...
IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA: Q1 Earnings Support Steady Optimism
IQVIA Holdings reported strong Q1 earnings with $3.83B in revenue, driven by growth in the Technology & Analytics Solutions segment, despite market pessimism. The company's profitability remains robus...
IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank...
IQVIA Holdings Inc. (IQV) Q1 2025 Earnings Call Transcript
IQVIA Holdings Inc. (NYSE:IQV) Q1 2025 Earnings Conference Call May 6, 2025 9:00 AM ET Company Participants Kerri Joseph - Senior Vice President, Investor Relations and Treasury Ari Bousbib - Chief E...
IQVIA Reports First-Quarter 2025 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and heal...